Condition: Huntington's Disease · Sponsor: Hoffmann-La Roche
This is a first-in-human (FIH) study of RG6496 that will assess the safety and tolerability of single-ascending doses of RG6496 administered to huntington's disease gene expansion carriers (HDGECs). The study consists of two parts: Part 1 \[single-ascending dose\] followed by Part 2 \[open-label extension (OLE)\].
This description comes directly from the study's public registry record.
Reference Study ID Number: BP45378 https://forpatients.roche.com/ · 888-662-6728 (U.S. Only) · global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry
Always discuss trial participation with your own doctor first.
| Hospital Britanico de Buenos Aires | Ciudad Autonoma Bs As, Argentina | Recruiting |
| Westmead Hospital | Westmead, New South Wales, Australia | Recruiting |
| Monash Health | Clayton, Victoria, Australia | Suspended |
| Royal Melbourne Hospital | Parkville, Victoria, Australia | Recruiting |
| New Zealand Brain Research Institute | Christchurch, New Zealand | Recruiting |
| Cambridge Centre for Brain Repair | Cambridge, Cambridgeshire, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07246941